Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

ABSTRACT:

Background

Phase III trials show sorafenib improves survival in advanced hepatocellular carcinoma (HCC). Because of narrow trial eligibility, results may not be generalizable to a broader HCC population. We sought to evaluate the effectiveness of initial sorafenib versus no treatment among Medicare beneficiaries with advanced HCC.

Materials and methods

Patients with advanced HCC diagnosed from 2008 to 2011 were identified from the Surveillance, Epidemiology, and End Results-Medicare database. Eligible patients received initial sorafenib or no therapy and were covered by Medicare parts A, B, and D. Sorafenib use and outcomes were described in this population. Using a propensity score (PS)-matched sample, we compared the effectiveness of sorafenib versus no treatment by Cox pr

SUBMITTER: Sanoff HK 

PROVIDER: S-EPMC5016063 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature